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Abstract
Background: The aetiology of central nervous system lesions observed in cerebral cyclosporine neurotoxicity remains 
controversial.
Case presentation: We report a 48-year-old woman with a non-severe aplastic anaemia who presented with stroke-
like episodes while on cyclosporine treatment.
Transcranial Doppler ultrasound revealed severely elevated flow velocities in several cerebral vessels, consistent with
vasospasm. Immediately after reducing the cyclosporine dose, the stroke-like episodes disappeared. Only after
cyclosporine withdrawal the transcranial Doppler ultrasound abnormalities fully resolved.
Conclusions: This case demonstrates a significant role of vasospasm in the pathway of cyclosporine-induced 
neurotoxicity. Transcranial Doppler ultrasound is an effective tool for the diagnosis and follow-up of cyclosporine-
induced vasospasm.
Background
Cyclosporine A is a potent immunosuppressive agent
used in various immunological disorders and is adminis-
tered to prevent graft rejection of transplantations[1].
Neurotoxicity is the second most common side effect of
cyclosporine after nephrotoxicity and appears in up to
60% of cyclosporine-treated patients[2]. Since predomi-
nantly the central nervous system is affected, the clinical
symptoms of cyclosporine-mediated neurotoxicity are
decreased responsiveness, hallucinations, delusions, sei-
zures, cortical blindness, aphasia, ataxia and stroke-like
episodes. Minor symptoms include tremor, agitation,
insomnia, anxiety, amnesia, headache, and paraesthe-
sias[1,2]. Central nervous system lesions caused by
cyclosporine are located in the border zones between
major vascular territories or their main branches[3].
Lesions can occur even when cyclosporine blood-
through levels are within the therapeutic range[2]. The
aetiology of the lesions observed in cerebral cyclosporine
neurotoxicity remains controversial.
Case presentation
A 48-year-old woman, with a medical history of a non-
severe aplastic anaemia, was re-admitted to the haema-
tology department. She recently had been treated with
horse antithymocyte globulin (15 mg/kg/day intrave-
nously for 5 days) in combination with high dose
cyclosporine and prednisolone, in order to prevent acute
serum sickness. Her current oral medication consisted of
cyclosporine 350 mg bidaily (6 mg/kg bidaily), predni-
sone 60 mg once daily, ciprofloxacin 500 mg bidaily and
fluconazole 200 mg once daily. At admission, she pre-
sented with stroke-like episodes; repetitive episodes of
sudden loss of strength in the left leg and numbness on
the left side of the face. The motor symptoms resolved
within a few minutes to one hour, although a cold feeling
in her left leg and left side of her face persisted. She
reported no other symptoms. Her vital signs, including
blood pressure (110/70 mmHg), remained within normal
range during these episodes. Neurological examination
directly after an episode, revealed no abnormalities
besides the disturbed temperature sensations. Further-
more, she was bi-cytopenic (haemoglobin level of 6.1
mmol/l with no schistocytes and thrombocyte count of
48 × 109/l) with normal leukocytes (white blood cell
count 4.4 × 109/l with 50% granulocytes). Besides the low
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thrombocyte count, there were no coagulation disorders.
Serum calcium level was 2.07 mmol/L (normal range 2.10
mmol/L-2.55 mmol/L) and serum magnesium level was
0.56 mmol/L (normal range 0.70 mmol/L-1.00 mmol/L),
for which replenishment was started. Serum cyclosporine
concentration was too high (0.64 mg/l, normal range of
0.10-0.30 mg/l); all other laboratory findings, including
renal function and cholesterol level, were normal. Elec-
trocardiogram, 24-hour Holter registration and cardiac
ultrasonography revealed no abnormalities. Brain mag-
netic resonance imaging revealed small hyperintense
punctuate foci in the watershed region of the right semio-
val centre up to the subcortical area between the anterior
and middle cerebral arteries (Figure 1A). Some of these
small foci showed restricted diffusion using diffusion
weighted imaging sequences (Figure 1B and 1C). Lumbar
puncture was unremarkable. Extracranial duplex exami-
nation showed no abnormalities in the carotid and verte-
bral arteries. Transcranial Doppler ultrasound revealed
segments of severely eleva ted flow velocities in several
cerebral vessels, particularly both middle cerebral arteries
(Figure 2A and 2B). These findings were consistent with
vasospasm. Based on the toxic cyclosporine concentra-
tion in absence of schistocytes (fragmented red blood
cells) with no signs of acute serum sickness and throm-
botic thrombocytopenic purpura, cyclosporine was
reduced with 20% and fluconazole and prednisone were
withdrawn. Immediately after reducing the cyclosporine
dose, the stroke-like episodes disappeared. One week
after the dose reduction serum cyclosporine concentra-
tion had normalized to 0.29 mg/l, but blood flow veloci-
ties as measured with transcranial Doppler ultrasound
were practically unchanged. Thereupon, cyclosporine
was withdrawn. Six weeks after discontinuation of treat-
ment the transcranial Doppler ultrasound abnormalities
had fully resolved (Figure 3A and 3B, and Additional file
1: supplemental table 1), the patient remained asymp-
tomatic, and had remission of aplastic anaemia.
Discussion
The specific distribution of the increased blood flow
velocities measured by transcranial Doppler ultrasound,
toxic cyclosporine levels and follow-up in our patient
clearly demonstrate a significant role of vasospasm in the
pathway of cyclosporine-induced neurotoxicity.
Although clinically unlikely, vasculitis or recanalized
stenoses of embolic origin may also cause the transcranial
Doppler ultrasound changes.
Previous authors have suggested hypertension, direct
neurotoxicity, thrombotic microangiopathy, metabolic
disturbances, or a combination of these factors as under-
lying pathophysiology of cyclosporine-induced neurotox-
icity[4]. A distinct clinical entity associated with
cyclosporine treatment is the "Posterior reversible
encephalopathy syndrome" (PRES). PRES is a syndrome
clinically characterized by headache, vomiting, confu-
sion, seizures, cortical blindness and other visual abnor-
Figure 2 Initial ultrasound findings. On figure 1A, the mainstem and one M2 segment of the left middle cerebral artery are depicted in colour mode 
using transcranial colour coded duplex sonography. Note the typical aliasing in the most proximal segment despite the rather insensitive setting of 
the colour scale, indicating a severely stenosed segment. On figure 1B, the Doppler spectogram as measured in that segment is given, indeed showing 
highly elevated blood flow velocities.
Figure 1 The axial FLAIR image (1A) shows small hyperintense 
foci in the watershed area in the right hemisphere. Some of these 
foci show high signal intensity on DWI (1B) and low signal intensity at 
the ADC-map (1C), consistent with restrictive diffusion (arrows).Braakman et al. BMC Neurology 2010, 10:30
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malities, and sometimes motor signs, with focal, often
symmetric vasogenic edema as its key radiological and
pathologic feature [5-8]. The vasogenic edema is thought
to result from epithelial dysfunction with vasoconstric-
tion, leukocyte trafficking, or both[9].
In this patient, we believe cyclosporine-induced vasos-
pasm induced this clinical disease. Magnetic resonance
imaging revealed focal restricted diffusion, indicative of
ischemia, rather than the vasogenic edema of PRES (Fig-
ure 1). If cyclosporine therapy is prolonged, the persisting
vasospasms may contribute to the development of true
PRES, through prolonged hypoxemia leading to endothe-
lial/cellular vascular endothelial growth factor expres-
sion, increased vascular permeability and ultimately
vasogenic edema. The role of the latter mechanism was
highlighted in a recent case report[10].
Although here used in a setting of aplastic anaemia,
these findings most likely pertain to all instances where
cyclosporine is used, including stem cell and solid organ
transplantation. Patients with aplastic anaemia or alloge-
neic stem cell transplantations receive higher dosages of
cyclosporine than solid organ transplanted patients.
Therefore, the former category may be at increased risk
of cyclosporine neurotoxicity including PRES vasogenic
edema.
Cyclosporine-induced neurotoxicity can present in var-
ious distinct clinical syndromes; vasospasm as a primary
or secondary phenomenon probably plays a key role. Tru-
wit et al were the first who suggested that vasospasm of
the intracranial arteries contributed to the mechanism of
neurotoxicity. They postulated that endothelial damage
plays a primary role, with the release of vasoactive pep-
tides leading to vasospasm as a secondary phenome-
non[11]. Later, magnetic resonance angiography was
used to assess vasospasm as a central mechanism of
cyclosporine neurotoxicity. Interestingly, the lumen nar-
rowing was reversible within weeks after therapy cessa-
tion[4,12,13]. A comparable temporal course was
observed in our patient and was also seen by Shbarou et
al who described the first two cases in which, next to
magnetic resonance angiography, transcranial Doppler
ultrasound was used to assess cyclosporine-induced
vasospasm[13].
Conclusions
Central nervous system dysfunction in patients receiving
cyclosporine should alert the neurologist to rule out
vasospasm of the main arteries of the circle of Willis.
Transcranial Doppler ultrasound is a readily available,
effective, non-invasive and low-cost tool for the diagnosis
and follow-up of cyclosporine-induced vasospasm. Early
diagnosis of cyclosporine neurotoxicity is important. The
process of vasospasm is reversible in its early stages but in
later stages it may become irreversible or even fatal[2].
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